BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Interest Expense

Cost of servicing the company's debt during the period.

BioAge Labs, Inc.NASDAQ: BIOA

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $39K fell 84.7% year over year, behind the -65.8% change in trailing-twelve-month interest expense. Sequentially, it fell 57.6% from the prior quarter. Over 3 fiscal years it compounded at +42.5% a year.

Context

  • Interest expense amounted to 7.7% of revenue in FY2025.
  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -84.7% toward the trailing-twelve-month pace of -65.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$39K-57.6% QoQ
Last fiscal yearDec 2025
$697K-70.6% YoY
LTMMar 2026
$481K-65.8% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-84.7%——
1 year-70.6%——
3-year CAGR+42.5%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
697K USD
Year-over-year change
-70.6%
3-year CAGR
+42.5%

Interest Expense vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -65.8% is the 7th highest of 8, against a peer median of +0.6%.
  • Interest expense amounts to 4.7% of revenue for BIOA, versus a peer median of 8.0%.
BIOA Competitors
Interest Expense for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$40.92M CAD-45.1%-32.9%13.1%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$22.88M USD—+12.0%16.9%
HUMAHumacyte, Inc.LTM Mar 2026$10.52M USD+0.6%+22.0%521.9%
ACBAurora Cannabis Inc.LTM Mar 2026CA$5.82M CAD-30.9%-64.2%1.9%
CABACabaletta Bio, Inc.LTM Mar 2026$2.35M USD+125.1%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$1.23M USD+270.1%——
TKNOAlpha Teknova, Inc.LTM Mar 2026$785K USD+14.4%—1.9%
BIOABioAge Labs, Inc.LTM Mar 2026$481K USD-65.8%+42.5%4.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
EDITEditas Medicine, Inc.LTM Mar 2026-$1.14M USD-151.6%—3.0%
Peer median (excluding BIOA) —+0.6%-10.4%8.0%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.